VIRxSYS Corp. is a holding company, which uses its proprietary platform technologies to develop therapies for serious human diseases. Its platform technologies include lentiviral vectors as a delivery vehicle for genes against certain diseases and for vaccine therapies. Its therapies are in various stages of development from pre-clinical through Phase II clinical trials. The company was founded by Boro Dropulic, William J. Turner, and Wiliam N. Sick Jr in 1998 and is headquartered in Gaithersburg, MD.

Intronn, Inc. operated as an RNA trans-splicing company. The company was headquartered in Gaithersburg, MD.

Eisai R&D Management Co., Ltd., a subsidiary of Eisai Co., Ltd., is a company headquartered in Bunkyo, Japan. The firm engages in research and development of pharmaceuticals.

Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well as agricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests.

The University of Iowa Research Foundation (UIRF) - a 501C3 corporation - commercializes University of Iowa developed technologies and inventions through licensing and new venture formation, and manages the subsequent revenue stream.

MicroDiag Biomedicine focuses on the treatment of cancer, Alzheimer's, acute infectious diseases, and other major diseases. The company was founded in 2008 and is headquartered in Suzhou, Jiangsu, China.

ProBioGen AG is a renowned Contract Development and Manufacturing Organization (CDMO) and technology provider with focus on cell line engineering, process development (upstream- and downstream process) and GMP manufacturing of biopharmaceuticals. Having almost 20 years of experience in mammalian cell culture, combined with innovative scientific excellence and a strong intellectual property base, we cover the entire drug development value chain, including regulatory support for IND-filing. All of our services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA). Founded in 1994, ProBioGen’s reputation is based on a highly dedicated specialist team who strives for excellence in quality and speed in every project. We are led by a seasoned management team with more than 60 years of experience in the biopharmaceutical industry. Beyond offering state-of-the-art, fee-for-service-based services from cell line development up to GMP manufacturing, we also developed various innovative technologies for optimized biopharmaceutical manufacturing and analysis.

Part of Bristol Myers Squibb Co., Aventis Research & Technologies GmbH & Co. KG is a company headquartered in Frankfurt, Germany, focused on noncommercial research organizations. On January 07, 2002 Phylos, Inc., a subsidiary of Bristol Myers Squibb Co. since March 2004, acquired Aventis Research & Technologies GmbH & Co. KG from Aventis SA.

BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. Its business scope ranges from scientific, health, agricultural and informatics. The company was founded by Wang Jian on September 9, 1999 and is headquartered in Shenzhen, China.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

BGI Shenzhen Co., Ltd. engages in the equity investment and asset management. Its business scope includes research and development and sales of computer hardware and software and peripheral equipment technology; import and export of goods and technology; equity investment; investment in industrial development; and aquatic product farming and sales. The company was founded on August 21, 2008 and is headquartered in Shenzhen, China.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Jiaxing Fraser Gene Information Co., Ltd., established on 2018-04-26, Business scope includes research and development of genetic information analysis technology,technology transfer;Gene information software development;Gene information consultation;Biotechnology R&D;Biological reagent research and development,technology transfer,technical consulting;Sales of biological reagent consumables;Engaged in the import and export of goods and technology(Goods and technologies prohibited by the state from import and export are not included).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Beijing Century World Biotechnology Co., Ltd., established on 2002-04-18, The business scope includes the sale of third-class medical devices;Production of the second class,Class III medical devices;Technical development of biological products,technology transfer,technical consulting,Technical Services;Import and export,Technology Import and Export;Sales of medical devices Class II,Equipment,Chemical Products(Does not contain dangerous chemicals and a class of precursor chemicals),Instrumentation,biological reagent(Free of Hazardous Chemicals);Machinery and Equipment Leasing(Car rental not included).(Market entities independently choose business projects in accordance with the law,Carry out business activities;Production of the second class,Class III medical devices,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Ogon (Guangzhou) Pump Co., Ltd., established on 2008-09-04, Business scope includes water treatment installation services;General Machinery Sales;Pump and vacuum equipment manufacturing;Mechanical parts processing;Other metal processing machinery manufacturing;Manufacture of special equipment for pulp and paper making;Fire Equipment,equipment manufacturing;Water resources special machinery manufacturing;Mechanical and Electrical Equipment Installation Services;Sewage Treatment and Its Reuse;Plumbing installation services(oil delivery,gas transmission,Water pipeline installation);Machinery Parts Wholesale;Instrument wholesale;Import and export(Excluding franchised products);